Menu Search
Equities

Oragenics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0A64:LSE

Oragenics Inc

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta1.1016
Data delayed at least 20 minutes, as of Jun 02 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Oragenics, Inc. is a development-stage company. It is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. It focuses on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI or Concussion), and for treating Niemann Pick Disease Type C (NPC), and proprietary powder formulation and an intranasal delivery device. Its lead product, ONP-002, is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. It is also focused on developing medical products that treat brain related illnesses and diseases (the Neurology Assets). Its other product candidate, ONP-001, is in its early stage and clinical trials.

  • Revenue in USD (TTM)0.00
  • Net income in USD-10.90m
  • Incorporated1996
  • Employees3.00
  • Location
    Oragenics Inc9015 TOWN CENTER PARKWAY, SUITE 143LAKEWOOD RANCH 34202United StatesUSA
  • Phone+1 (813) 286-7900
  • Fax+1 (813) 286-7904
  • Websitehttps://www.oragenics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.